Clinical Trials

475 enrolled

Urinary Bladder Neoplasms

NCT04164082 2026-03-18

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

161 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms

NCT04491942 2026-03-18

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

74 enrolled

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT06211764 2026-03-17

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

220 enrolled

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

33 enrolled

Urinary Bladder Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

34 enrolled

Urinary Bladder Neoplasms

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

470 enrolled

Urinary Bladder Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT01104350 2026-03-05

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Phase 1 Completed

19 enrolled

Urinary Bladder Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03609216 2026-03-04

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

271 enrolled

Infiltrating Bladder Urothelial Carcinoma

NCT07000084 2026-03-04

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07393542 2026-03-03

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

462 enrolled

Carcinoma, Transitional Cell

NCT05538663 2026-03-02

BRIDGE

870 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

25 enrolled

Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Urinary Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT03967977 2026-01-26

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

46 enrolled

Urinary Bladder Neoplasms

NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Completed

51 enrolled

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

54 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01352962 2026-01-05

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase 1 Completed

18 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Recruiting

178 enrolled

Carcinoma, Transitional Cell

NCT07296705 2025-12-22

HARBOR

25 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

28 enrolled

Urinary Bladder Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

95 enrolled

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

57 enrolled

DermatologicGenitourinarySarcoma

Carcinoma, Transitional Cell

NCT03093909 2025-11-10

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

44 enrolled

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT03288545 2025-11-10

EV-103

Phase 1/2 Active not recruiting

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT00479128 2025-10-28

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

80 enrolled